Table of Content

1. Key Insight

2. Executive Summary

3. Uveitis Market Overview at a Glance
3.1. Market Share (%) Distribution of Uveitis in 2017
3.2. Market Share (%) Distribution of Uveitis in 2030

4. Disease Background and Overview: Uveitis
4.1. Introduction
4.2. Classification of Uveitis
4.3. International Uveitis Study Group (IUSG) Clinical Classification of Uveitis
4.4. The Standardization of Uveitis Nomenclature (SUN) Working Group
4.5. Symptoms of Uveitis
4.6. Pathophysiology
4.7. Etiology of Uveitis
4.8. Diagnosis of Uveitis
American Academy of Family Physicians

5. Case Reports
5.1. A Case Study of Unusual Etiology of Anterior Uveitis with Ocular Hypertension-Iris Metastasis of Primary Lung Adenocarcinoma
5.2. Blurry Vision and a Black Ink Tattoo
5.3. Psoriatic Juvenile Idiopathic Arthritis Associated with Uveitis: A Case Report
5.4. A Case of Syphilitic Uveitis in Which Vitreous Surgery Was Useful for the Diagnosis and Treatment

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Epidemiology Methodology
6.3. Prevalent Population of Uveitis in the 7MM
6.4. Diagnosed Prevalent Population of Uveitis in the 7MM
6.5. Type-specific Diagnosed Prevalent Population of Uveitis in the 7MM

7. United States-Epidemiology of Uveitis
7.1. Assumptions and Rationale
7.2. Total Prevalent Population of Uveitis in the United States
7.3. Diagnosed Prevalent Population of Uveitis in the United States
7.4. Gender-specific Diagnosed Prevalent Population of Uveitis in the United States
7.5. Age-specific Diagnosed Prevalent Population of Uveitis in the United States
7.6. Type-specific Diagnosed Prevalent Population of Uveitis in the United States
7.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
7.8. Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the United States

8. EU-5 Epidemiology of Uveitis
8.1. Germany
8.1.1. Assumptions and Rationale
8.1.2. Prevalent Population of Uveitis in Germany
8.1.3. Diagnosed Prevalent Population of Uveitis in Germany
8.1.4. Gender-specific Diagnosed Prevalence of Uveitis in Germany
8.1.5. Age-specific Diagnosed Prevalence of Uveitis in Germany
8.1.6. Type-specific Diagnosed Prevalence of Uveitis in Germany
8.1.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
8.1.8. Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany
8.2. France
8.2.1. Assumptions and Rationale
8.2.2. Prevalent Population of Uveitis in France
8.2.3. Diagnosed Prevalent Population of Uveitis in France
8.2.4. Gender-specific Diagnosed Prevalence of Uveitis in France
8.2.5. Age-specific Diagnosed Prevalence of Uveitis in France
8.2.6. Type-specific Diagnosed Prevalence of Uveitis in France
8.2.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
8.2.8. Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France
8.3. Italy
8.3.1. Assumptions and Rationale
8.3.2. Prevalent Population of Uveitis in Italy
8.3.3. Diagnosed Prevalent Population of Uveitis in Italy
8.3.4. Gender-specific Diagnosed Prevalence of Uveitis in Italy
8.3.5. Age-specific Diagnosed Prevalence of Uveitis in Italy
8.3.6. Type-specific Diagnosed Prevalence of Uveitis in Italy
8.3.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location
8.3.8. Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy
8.4. Spain
8.4.1. Assumptions and Rationale
8.4.2. Prevalent Population of Uveitis in Spain
8.4.3. Diagnosed Prevalent Population of Uveitis in Spain
8.4.4. Gender-specific Diagnosed Prevalence population of Uveitis in Spain
8.4.5. Age-specific Diagnosed Prevalence of Uveitis in Spain
8.4.6. Type-specific Diagnosed Prevalence of Uveitis in Spain
8.4.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain
8.4.8. Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain
8.5. United Kingdom
8.5.1. Assumptions and Rationale
8.5.2. Prevalent Population of Uveitis in the UK
8.5.3. Diagnosed Prevalent Population of Uveitis in the United Kingdom
8.5.4. Gender-specific Diagnosed Prevalence of Uveitis in the UK
8.5.5. Age-specific Diagnosed Prevalence of Uveitis in the UK
8.5.6. Type-specific Diagnosed Prevalence of Uveitis in the UK
8.5.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the UK
8.5.8. Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the UK

9. Japan
9.1. Assumptions and Rationale
9.2. Prevalent Population of Uveitis in Japan
9.3. Diagnosed Prevalent Population of Uveitis in Japan
9.4. Gender-specific Prevalence of Uveitis in Japan
9.5. Age-specific Prevalence of Uveitis in Japan
9.6. Type-specific Prevalence of Uveitis in Japan
9.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan
9.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan

10. Treatment of Uveitis
10.1. Treatment Algorithm
10.2. First Line of Therapy: Corticosteroids
10.3. Second Line of Therapy: Immunosuppressants
10.4. Third Line of Therapy: Biologics
10.5. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals of Care for Uveitis (FOCUS) Initiative

11. Unmet Needs

12. Marketed Drugs
12.1. Key Cross Competition
12.2. Durezol: Sirion Therapeutics
12.2.1. Product Description
12.2.2. Regulatory Milestones
12.2.3. Advantages & Disadvantages
12.2.4. Safety and Efficacy
12.2.5. Product Profile
12.3. Triesence: Novartis
12.3.1. Drug Description
12.3.2. Regulatory Milestones
12.3.3. Advantages & Disadvantages
12.3.4. Safety and Efficacy
12.3.5. Product Profile
12.4. Retisert: Valeant Pharmaceuticals International Inc
12.4.1. Drug Description
12.4.2. Regulatory Milestones
12.4.3. Advantages & Disadvantages
12.4.4. Safety
12.4.5. Efficacy
12.4.6. Product Profile
12.5. Ozurdex: Allergan plc
12.5.1. Drug Description
12.5.2. Regulatory Milestones
12.5.3. Advantages and Disadvantages
12.5.4. Efficacy
12.5.5. Safety
12.5.6. Product Profile
12.6. Humira: AbbVie Inc.
12.6.1. Drug Description
12.6.2. Regulatory Milestones
12.6.3. Advantages & Disadvantages
12.6.4. Safety and Efficacy
12.6.5. Product Profile
12.7. Yutiq: Eyepoint Pharmaceuticals
12.7.1. Product Description
12.7.2. Regulatory Milestones
12.7.3. Clinical Development
12.7.4. Advantages & Disadvantages
12.7.5. Safety and Efficacy
12.7.6. Product Profile
12.8. Tobradex: Alcon Laboratories
12.8.1. Product Description
12.8.2. Other Developmental Activities
12.8.3. Product Profile
12.9. Acthar: Mallinckrodt
12.9.1. Product Description
12.9.2. Other Developmental Activities
12.9.3. Advantages and Disadvantages
12.9.4. Safety and Efficacy
12.9.5. Product Profile
12.10. Iluvien: Alimera Sciences
12.10.1. Product Description
12.10.2. Other Developmental Activities
12.10.3. Clinical Development
12.10.4. Clinical Trials Information
12.10.5. Safety and Efficacy
12.10.6. Product Profile
13. Emerging Drugs Analysis
13.1. Key Cross Competition
13.2. Reproxalap/ADX-102: Aldeyra Therapeutics Inc.
13.2.1. Product Description
13.2.2. Advantages and Disadvantages
13.2.3. Clinical Development
13.2.4. Safety and Efficacy
13.2.5. Product Profile
13.3. Sirolimus: Santen
13.3.1. Product Description
13.3.2. Regulatory Milestones
13.3.3. Advantages and Disadvantages
13.3.4. Clinical Development
13.3.5. Safety and Efficacy
13.3.6. Product Profile
13.4. EGP-437: EyeGate Pharmaceuticals
13.4.1. Product Description
13.4.2. Regulatory Milestones
13.4.3. Advantages and Disadvantages
13.4.4. Clinical Development
13.4.5. Safety and Efficacy
13.4.6. Product Profile
13.5. XIPERE/Suprachoroidal CLS-TA: Clearside Biomedical, Inc.
13.5.1. Product Description
13.5.2. Regulatory Milestones
13.5.3. Clinical Development
13.5.4. Safety and Efficacy
13.5.5. Product Profile
13.6. Sarilumab: Sanofi Aventis
13.6.1. Product Description
13.6.2. Product Development Activities
13.6.3. Advantages and Disadvantages
13.6.4. Clinical Development
13.6.5. Safety and Efficacy
13.6.6. Product Profile
13.7. LME636 (OCS-02): Oculis Pharma
13.7.1. Product Description
13.7.2. Other development activities
13.7.3. Clinical Development
13.7.4. Safety and Efficacy
13.7.5. Product Profile
13.8. LFG316: Novartis
13.8.1. Product Description
13.8.2. Other development activities
13.8.3. Clinical Development
13.8.4. Safety and Efficacy
13.8.5. Product Profile
13.9. Abatacept (Orenica): Bristol-Myers Squibb Company
13.9.1. Product Description
13.9.2. Clinical Development
13.9.3. Safety and Efficacy
13.9.4. Product Profile
13.10. EYS606: Eyevensys
13.10.1. Product Description
13.10.2. Other development activities
13.10.3. Clinical Development
13.10.4. Safety and Efficacy
13.10.5. Product Profile

14. Uveitis: Seven Major Market Analysis
14.1. Key Findings
14.2. Market Size of Uveitis in the 7MM
14.3. Market Size of Uveitis by Therapies in the 7MM

15. United States: Market Outlook
15.1. Total Market size of Uveitis
15.2. Uveitis Market Size by Therapies

16. EU5: Market Outlook
16.1. Germany Market Size
16.1.1. Total Market size of Uveitis
16.1.2. Uveitis Market Size by Therapies
16.2. France Market Size
16.2.1. Total Market size of Uveitis
16.2.2. Uveitis Market Size by Therapies
16.3. Italy Market Size
16.3.1. Total Market size of Uveitis
16.3.2. Uveitis Market Size by Therapies
16.4. Spain Market Size
16.4.1. Total Market size of Uveitis
16.4.2. Uveitis Market Size by Therapies
16.5. United Kingdom Market Size
16.5.1. Total Market size of Uveitis
16.5.2. Uveitis Market Size by Therapies

17. Japan: Market Outlook
17.1. Japan: Market Size
17.1.1. Total Market size of Uveitis
17.1.2. Uveitis Market Size by Therapies

18. Market Drivers

19. Market Barriers

20. Reimbursement and Market Access
21. KOL Views
22. Appendix
23. Report Methodology
23.1. Sources Used
24. DelveInsight Capabilities
25. Disclaimer
26. About DelveInsight



List of Figures


Figure 1 Structure of Eye
Figure 2 Types of Uveitis and Affected area
Figure 3 Classification of Uveitis
Figure 4 Types of Uveitis are based on the different parts of eye. Below are the four types
Figure 5 Symptoms of Uveitis
Figure 6 Pathogenetic mechanism of Uveitis
Figure 7 Mechanism of antigen processing and presentation.
Figure 8 Autoimmune conditions that cause uveitis
Figure 9 Causes of Uveitis
Figure 10 Diagnosis algorithm for Uveitis
Figure 11 Prevalent Population of Uveitis in the 7MM (2017–2030)
Figure 12 Diagnosed Prevalent Population of Uveitis in the 7MM (2017–2030)
Figure 13 Type-specific Diagnosed Prevalent Population of Uveitis in the 7MM (2017–2030)
Figure 14 Total Prevalent Population of Uveitis in the United States (2017–2030)
Figure 15 Diagnosed Prevalent Population of Uveitis in the United States (2017–2030)
Figure 16 Gender-specific Diagnosed Prevalent Population of Uveitis in the United States (2017–2030)
Figure 17 Age-specific Diagnosed Prevalent Population of Uveitis in the United States (2017–2030)
Figure 18 Type-specific Diagnosed Prevalent Population of Uveitis in the US (2017–2030)
Figure 19 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the United States (2017–2030)
Figure 20 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the United States (2017–2030)
Figure 21 Prevalent Population of Uveitis in Germany (2017–2030)
Figure 22 Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)
Figure 23 Gender-specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)
Figure 24 Age-specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)
Figure 25 Type-specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)
Figure 26 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Germany (2017–2030)
Figure 27 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany 2017–2030)
Figure 28 Prevalent Population of Uveitis in France (2017–2030)
Figure 29 Diagnosed Prevalent Population of Uveitis in France (2017–2030)
Figure 30 Gender-specific Diagnosed Prevalent Population of Uveitis in France (2017–2030)
Figure 31 Age-specific Diagnosed Prevalent Population of Uveitis in France (2017–2030)
Figure 32 Type-specific Diagnosed Prevalent Population of Uveitis in France (2017–2030)
Figure 33 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in France (2017–2030)
Figure 34 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France (2017–2030)
Figure 35 Prevalent Population of Uveitis in Italy (2017–2030)
Figure 36 Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)
Figure 37 Gender-specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)
Figure 38 Age-specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)
Figure 39 Type-specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)
Figure 40 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Italy (2017–2030)
Figure 41 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy (2017–2030)
Figure 42 Prevalent Population of Uveitis & Non-Infectious Uveitis (NIU) in Spain (2017–2030)
Figure 43 Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)
Figure 44 Gender-specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)
Figure 45 Age-specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)
Figure 46 Type-specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)
Figure 47 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain (2017–2030)
Figure 48 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain (2017–2030)
Figure 49 Prevalent Population of Uveitis in the UK (2017–2030)
Figure 50 Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)
Figure 51 Gender-specific Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)
Figure 52 Age-specific Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)
Figure 53 Type-specific Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)
Figure 54 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the UK (2017–2030)
Figure 55 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the UK (2017–2030)
Figure 56 Prevalent Population of Uveitis in Japan (2017–2030)
Figure 57 Diagnosed Prevalent Population of Uveitis in Japan (2017–2030)
Figure 58 Gender-specific Prevalent Population of Uveitis in Japan (2017–2030)
Figure 59 Age-specific Prevalent Population of Uveitis in Japan (2017–2030)
Figure 60 Type Specific Prevalent Population of Uveitis in Japan (2017–2030)
Figure 61 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan (2017-2030)
Figure 62 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan (2017–2030)
Figure 63 Treatment Regimens
Figure 64 Treatment Algorithm of Uveitis
Figure 65 Therapeutic algorithm in endogenous Anterior Uveitis (AU)
Figure 66 Therapeutic algorithm in endogenous Intermediate Uveitis (IU)
Figure 67 Therapeutic algorithm in immune-mediated posterior uve?tis or panuveiti
Figure 68 Management flowchart for non-infectious uveitis
Figure 69 Unmet Needs
Figure 70 Market size of Uveitis by Region in USD Million (2017–2030)
Figure 71 Market Size of Uveitis by Therapies in the 7MM, in USD Million (2017–2030)
Figure 72 Market Size of Uveitis in the United States, USD Million (2017–2030)
Figure 73 The United States Uveitis Market Size by Therapies in USD Million (2017–2030)
Figure 74 Market Size of Uveitis in Germany, USD Million (2017–2030)
Figure 75 Market Size of Uveitis by Therapies in Germany, in USD Million (2017–2030)
Figure 76 Market Size of Uveitis in France, USD Million (2017–2030)
Figure 77 France Uveitis Market Size by Therapies in USD Million (2017–2030)
Figure 78 Market Size of Uveitis in Italy, USD Million (2017–2030)
Figure 79 Italy Uveitis Market Size by Therapies in USD Million (2017–2030)
Figure 80 Market Size of Uveitis in Spain, USD Million (2017–2030)
Figure 81 Spain Uveitis Market Size by Therapies in USD Million (2017–2030)
Figure 82 Market Size of Uveitis in United Kingdom, USD Million (2017–2030)
Figure 83 United Kingdom Uveitis Market Size by Therapies in USD Million (2017–2030)
Figure 84 Market Size of Uveitis in Japan, USD Million (2017–2030)
Figure 85 Japan Uveitis Market Size by Therapies in USD Million (2017–2030)
Figure 86 Market Drivers of Uveitis
Figure 87 Market Barriers of Uveitis
Figure 88 KOL Views
Figure 89 United States KOL Views Uveitis
Figure 90 EU5 KOL Views

 

List of Tables


Table 1 Summary of Uveitis, Market, Epidemiology and Key Events (2017–2030)
Table 2 IUSG Clinical Classification of Uveitis
Table 3 The SUN Working Group Anatomic Classification of Uveitis
Table 4 The SUN Working Group Descriptors of Uveitis
Table 5 The SUN Working Group Grading Scheme for Anterior Chamber Cells
Table 6 The SUN Working Group Grading Scheme for Anterior Chamber Cells
Table 7 KEY RECOMMENDATIONS FOR PRACTICE
Table 8 Region-wise Prevalent Population of Uveitis (2017–2030)
Table 9 Diagnosed Prevalent Population of Uveitis (2017–2030)
Table 10 Type-specific Diagnosed Prevalent Population of Uveitis in the 7MM (2017–2030)
Table 11 Total Prevalent Population of Uveitis in the US (2017–2030)
Table 12 Total Diagnosed Prevalent Population of Uveitis in the US (2017–2030)
Table 13 Gender-specific Diagnosed Prevalent Population of Uveitis in the US (2017–2030)
Table 14 Age-specific Diagnosed Prevalent Population of Uveitis in the US (2017–2030)
Table 15 Type-specific Diagnosed Prevalent Population of Uveitis in the US (2017–2030)
Table 16 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the United States (2017–2030)
Table 17 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the United States (2017–2030)
Table 18 Prevalent Population of Uveitis in Germany (2017–2030)
Table 19 Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)
Table 20 Gender-specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)
Table 21 Age-specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)
Table 22 Type-specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)
Table 23 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Germany (2017–2030)
Table 24 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany (2017–2030)
Table 25 Prevalent Population of Uveitis in France (2017–2030)
Table 26 Diagnosed Prevalent Population of Uveitis in France (2017–2030)
Table 27 Gender-specific Diagnosed Prevalent Population of Uveitis in France (2017–2030)
Table 28 Age-specific Diagnosed Prevalent Population of Uveitis in France (2017–2030)
Table 29 Type-specific Diagnosed Prevalent Population of Uveitis in France (2017–2030)
Table 30 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in France (2017–2030)
Table 31 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France (2017–2030)
Table 32 Prevalent Population of Uveitis in Italy (2017–2030)
Table 33 Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)
Table 34 Gender-specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)
Table 35 Age-specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)
Table 36 Type-specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)
Table 37 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Italy (2017–2030)
Table 38 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy (2017–2030)
Table 39 Prevalent Population of Uveitis in Spain (2017–2030)
Table 40 Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)
Table 41 Gender-specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)
Table 42 Age-specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)
Table 43 Type-specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)
Table 44 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain (2017–2030)
Table 45 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain (2017–2030)
Table 46 Prevalent Population of Uveitis in the UK (2017–2030)
Table 47 Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)
Table 48 Gender-specific Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)
Table 49 Age-specific Prevalent Population of Uveitis in the UK (2017–2030)
Table 50 Type-specific Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)
Table 51 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the UK (2017–2030)
Table 52 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the UK (2017–2030)
Table 53 Prevalent Population of Uveitis in Japan (2017–2030)
Table 54 Diagnosed Prevalent Population of Uveitis in Japan (2017–2030)
Table 55 Gender-specific Prevalent Population of Uveitis in Japan (2017–2030)
Table 56 Age-specific Prevalent Population of Uveitis in Japan (2017–2030)
Table 57 Type-specific Prevalent Population of Uveitis in Japan (2017–2030)
Table 58 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan (2017-2030)
Table 59 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan (2017–2030)
Table 60 First Line of Therapy of the Treatment of Uveitis, 2020
Table 61 Marketed Drugs for Uveitis
Table 62 Tobradex, Clinical Trial Description, 2020
Table 63 Emerging Drugs Analysis
Table 64 ADX-102, Clinical Trial Description, 2020
Table 65 Sirolimus, Clinical Trial Description, 2020
Table 66 EGP 437, Clinical Trial Description, 2020
Table 67 Suprachoroidal CLS-TA, Clinical Trial Description, 2020
Table 68 Sarilumab, Clinical Trial Description, 2020
Table 69 LME636, Clinical Trial Description, 2020
Table 70 LFG316, Clinical Trial Description, 2020
Table 71 Abatacept, Clinical Trial Description, 2020
Table 72 EYS606, Clinical Trial Description, 2020
Table 73 Market size of Uveitis by Region in USD Million (2017–2030)
Table 74 Market Size of Uveitis by Therapies in 7MM, in USD Million (2017–2030)
Table 75 Market Size of Uveitis in the United States, USD Million (2017–2030)
Table 76 The United States Uveitis Market Size by Therapies in USD Million (2017–2030)
Table 77 Market Size of Uveitis in Germany, USD Million (2017–2030)
Table 78 Market Size of Uveitis by Therapies in Germany, in USD Million (2017–2030)
Table 79 Market Size of Uveitis in France, USD Million (2017–2030)
Table 80 Market Size of Uveitis by Therapies in France, in USD Million (2017–2030)
Table 81 Market Size of Uveitis in Italy, USD Million (2017–2030)
Table 82 Market Size of Uveitis by Therapies in Italy, in USD Million (2017–2030)
Table 83 Market Size of Uveitis in Spain, USD Million (2017–2030)
Table 84 Market Size of Uveitis by Therapies in Spain, in USD Million (2017–2030)
Table 85 Market Size of Uveitis in UK, USD Million (2017–2030)
Table 86 Market Size of Uveitis by Therapies in the United Kingdom, in USD Million (2017–2030)
Table 87 Market Size of Uveitis in Japan, USD Million (2017–2030)
Table 88 Market Size of Uveitis by Therapies in Japan, in USD Million (2017–2030)